TW202327625A - 用地西他濱及西屈嘧啶治療骨髓發育不良症候群之方法 - Google Patents

用地西他濱及西屈嘧啶治療骨髓發育不良症候群之方法 Download PDF

Info

Publication number
TW202327625A
TW202327625A TW111135794A TW111135794A TW202327625A TW 202327625 A TW202327625 A TW 202327625A TW 111135794 A TW111135794 A TW 111135794A TW 111135794 A TW111135794 A TW 111135794A TW 202327625 A TW202327625 A TW 202327625A
Authority
TW
Taiwan
Prior art keywords
effective amount
decitabine
cidronidine
survival
leukemia
Prior art date
Application number
TW111135794A
Other languages
English (en)
Chinese (zh)
Inventor
哈洛德 科特
穆罕默德 阿薩
洋 郝
Original Assignee
日商大塚製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大塚製藥股份有限公司 filed Critical 日商大塚製藥股份有限公司
Publication of TW202327625A publication Critical patent/TW202327625A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111135794A 2021-09-21 2022-09-21 用地西他濱及西屈嘧啶治療骨髓發育不良症候群之方法 TW202327625A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163246547P 2021-09-21 2021-09-21
US63/246,547 2021-09-21

Publications (1)

Publication Number Publication Date
TW202327625A true TW202327625A (zh) 2023-07-16

Family

ID=85721229

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111135794A TW202327625A (zh) 2021-09-21 2022-09-21 用地西他濱及西屈嘧啶治療骨髓發育不良症候群之方法

Country Status (10)

Country Link
US (1) US20250000888A1 (cg-RX-API-DMAC7.html)
EP (1) EP4404940A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024531799A (cg-RX-API-DMAC7.html)
KR (1) KR20240064656A (cg-RX-API-DMAC7.html)
CN (1) CN118201622A (cg-RX-API-DMAC7.html)
AU (1) AU2022348907B2 (cg-RX-API-DMAC7.html)
CA (1) CA3232623A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003537A (cg-RX-API-DMAC7.html)
TW (1) TW202327625A (cg-RX-API-DMAC7.html)
WO (1) WO2023049731A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548303A (ja) 2020-10-29 2023-11-16 大塚製薬株式会社 癌を処置する為の医薬組成物及びその使用方法
AU2024265282A1 (en) * 2023-05-02 2025-12-18 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708264C (en) * 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US10683552B2 (en) * 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
WO2021113688A1 (en) * 2019-12-05 2021-06-10 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of myelodysplastic syndrome
EP4090335A1 (en) * 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
LT4069254T (lt) * 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną

Also Published As

Publication number Publication date
JP2024531799A (ja) 2024-08-29
US20250000888A1 (en) 2025-01-02
AU2022348907B2 (en) 2026-07-16
WO2023049731A2 (en) 2023-03-30
AU2022348907A1 (en) 2024-04-11
WO2023049731A3 (en) 2023-05-04
CN118201622A (zh) 2024-06-14
EP4404940A4 (en) 2025-07-30
MX2024003537A (es) 2024-05-03
EP4404940A2 (en) 2024-07-31
CA3232623A1 (en) 2023-03-30
KR20240064656A (ko) 2024-05-13

Similar Documents

Publication Publication Date Title
TWI729492B (zh) 使用包含微脂體伊立替康(irinotecan)的組合療法治療胰臟癌的方法
CN114727996A (zh) 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
US11786543B2 (en) Compositions comprising decitabine and tetrahydrouridine and uses thereof
TWI912283B (zh) 地西他濱及西屈嘧啶(cedazuridine)組合之固體口服劑型
US20250000888A1 (en) Methods of treating myelodysplastic syndromes with decitabine and cedazuridine
US11938143B2 (en) Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
JP2025098099A (ja) ブルトン型チロシンキナーゼ阻害剤の投薬
CN103260415A (zh) 治疗小细胞肺癌的方法
US9265785B2 (en) Compositions comprising decitabine and tetrahydrouridine and uses thereof
WO2013086002A1 (en) Compositions, process of preparation of said compositions and method of treating cancer
WO2013022257A2 (ko) 피라지노-트리아진 유도체를 포함하는 비소세포성폐암 예방 및 치료용 조성물
HK40105549A (en) Methods of treating myelodysplastic syndromes with decitabine and cedazuridine
JP2022513320A (ja) Flt3が変異した血液のがんを処置する方法
EP1679076A1 (en) Compounds useful in the treatment of HIV
US20200306285A1 (en) Methods for treating cancer using purine analogs by depleting intracellular atp
WO2020239478A1 (en) Trabectedin for treating sarcomas based on genomic markers
US20050113384A1 (en) Combinations of (a) an atp-competitive inhibitor of c-acl kinase activity with (b) two or more other antineoplastic agents